Diagnostic and Predictive Values of IL-6 in a Group of Iraqi Patients with Rheumatoid Arthritis

Abeer M. Mohammed; Sarmad M. Zayni; Muhammad M. AL-Anee; Faiq I. Corial; Adnan Al- Rubaee

doi:10.32007/jfacmedbagdad.2044

Authors

Abeer M. Mohammed Ministry of Health, Diyala Teaching Hospital, Diyla, Iraq. https://orcid.org/0009-0003-3556-309X
Sarmad M. Zayni Department. of Microbiology,College of Medicine, University of Baghdad, Baghdad,Iraq. https://orcid.org/0000-0002-1976-9157
Muhammad M. AL-Anee Department of Microbiology, College of Medicine, Baghdad University, Baghdad, Iraq. https://orcid.org/0000-0001-5376-3229
Faiq I. Corial Department of Medicine, College of Medicine , University of Bagghdad, Baghdad, Iraq.
Adnan Al- Rubaee Department. of Poultry Science, University of Arkansas, Fayetteville USA .

DOI:

https://doi.org/10.32007/jfacmedbagdad.2044

Keywords:

Rheumatoid arthritis (RA),, cytokines, IL-6

Abstract

Background: Researchers have found that interleukin 6 (IL-6) plays a crucial regulatory function in the onset and progression of a wide range of inflammatory disorders. One of the more prevalent inflammatory illnesses affecting people today is rheumatoid arthritis.

Objective: The purpose of this study was to compare the IL-6 levels of rheumatoid arthritis (RA) patients to those of healthy controls and to examine the relationship between IL-6 and RA-related demographic and clinical factors.

Methods: A total of 80 participants: 40 rheumatoid arthritis (RA) sufferers and 40 healthy controls, all of whom ranged in age from 23 to 61. The serum concentrations of (IL-6) were analyzed using an enzyme-linked immunosorbent assay (ELISA).

Results: Increased IL-6 blood levels were associated with rheumatoid arthritis, suggesting that this biomarker may be useful for diagnosing the disease at an early stage. There was no statistically significant correlation between disease severity and the DAS28 score and IL-6 levels in the serum.

Conclusion: The cytokine interleukin 6 (IL-6) has been proposed as a biomarker and possible player in the etiology of rheumatoid arthritis.

Received:Dec.,,2022

Accepted: Feb. , 2023

Published: April 2023

Downloads

Download data is not yet available.

References

McInnes IB, Schett G. Pathogenetic insights from the treatment of rheumatoid arthritis. The Lancet. 2017 Jun 10;389(10086):2328-37. https://doi.org/10.1016/S0140-6736(17)31472-1

Matcham F, Scott IC, Rayner L, Hotopf M, Kingsley GH, Norton S, et al. The impact of rheumatoid arthritis on quality-of-life assessed using the SF-36: a systematic review and meta-analysis. In: Seminars in arthritis and rheumatism 2014 Oct 1 (Vol. 44, No. 2, pp. 123-130). WB Saunders. https://doi.org/10.1016/j.semarthrit.2014.05.001

Calabresi E, Petrelli F, Bonifacio AF, Puxeddu I, Alunno A. One year in review 2018: pathogenesis of rheumatoid arthritis. Clin Exp Rheumatol. 2018 May;36(2):175-84.

Di Sante G, Tolusso B, Fedele AL, Gremese E, Alivernini S, Nicolò C, et al. Collagen specific T-cell repertoire and HLA-DR alleles: biomarkers of active refractory rheumatoid arthritis. EBioMedicine. 2015 Dec 1;2(12):2037-45.

https://doi.org/10.1016/j.ebiom.2015.11.019

Hendler A, Mulli TK, Hughes FJ, Perrett D, Bombardieri M, Houri-Haddad Y, et al. Involvement of autoimmunity in the pathogenesis of aggressive periodontitis. Journal of dental research. 2010 Dec;89(12):1389-94. https://doi.org/10.1177/0022034510381903

Su R, Li Z, Wang Y, Liu Y, Zheng X, Gao C, et al. Imbalance between Th17 and regulatory T cells in patients with systemic lupus erythematosus combined EBV/CMV viraemia. Clinical and Experimental Rheumatology. 2019 Nov 20;38(5):864-73.

Persson GR. Rheumatoid arthritis and periodontitis-inflammatory and infectious connections. Review of the literature. Journal of oral microbiology. 2012 Jan 1;4(1):11829. https://doi.org/10.3402/jom.v4i0.11829

Franza L, Carusi V, Altamura S, Gasbarrini A, Caraffa A, Kritas SK, et al. Gut microbiota and immunity in common variable immunodeficiency: Crosstalk with pro-inflammatory cytokines. J. Biol. Regul. Homeost. Agents. 2019 Mar 1;33(2):315-9.

du Teil Espina M, Gabarrini G, Harmsen HJ, Westra J, van Winkelhoff AJ, van Dijl JM. Talk to your gut: the oral-gut microbiome axis and its immunomodulatory role in the etiology of rheumatoid arthritis. FEMS microbiology reviews. 2019 Jan;43(1):1-8.

https://doi.org/10.1093/femsre/fuy035

Zhang X, Zhang D, Jia H, Feng Q, Wang D, Liang D, et al. The oral and gut microbiomes are perturbed in rheumatoid arthritis and partly normalized after treatment. Nature medicine. 2015 Aug;21(8):895-905. https://doi.org/10.1038/nm.3914

Kang S, Narazaki M, Metwally H, Kishimoto T. Historical overview of the interleukin-6 family cytokine. Journal of Experimental Medicine. 2020 May 4;217(5). https://doi.org/10.1084/jem.20190347

Pandolfi F, Altamura S, Frosali S, Conti P. Key role of DAMP in inflammation, cancer, and tissue repair. Clinical therapeutics. 2016 May 1;38(5):1017-28. https://doi.org/10.1016/j.clinthera.2016.02.028

Wright HL, Cross AL, Edwards SW, Moots RJ. Effects of IL-6 and IL-6 blockade on neutrophil function in vitro and in vivo. Rheumatology. 2014 Jul 1;53(7):1321-31.. https://doi.org/10.1093/rheumatology/keu035

Matsunami M, Ubara Y, Sumida K, Oshima Y, Oguro M, Kinoshita K, et al. The efficacy and safety of anti-interleukin-6 receptor monoclonal blockade in a renal transplant patient with Castleman disease: early post-transplant outcome. BMC nephrology. 2018 Dec;19(1):1-5. https://doi.org/10.1186/s12882-018-1065-4

Hunter CA, Jones SA. IL-6 as a keystone cytokine in health and disease. Nature immunology. 2015 May;16(5):448-57.

https://doi.org/10.1038/ni.3153

Narazaki M, Kishimoto T. The two-faced cytokine IL-6 in host defense and diseases. International journal of molecular sciences. 2018 Nov 9;19(11):3528. https://doi.org/10.3390/ijms19113528

Tanaka T, Narazaki M, Kishimoto T. IL-6 in inflammation, immunity, and disease. Cold Spring Harbor perspectives in biology. 2014 Oct 1;6(10):a016295.. https://doi.org/10.1101/cshperspect.a016295

Wright HL, Cross AL, Edwards SW, Moots RJ. Effects of IL-6 and IL-6 blockade on neutrophil function in vitro and in vivo. Rheumatology. 2014 Jul 1;53(7):1321-31. https://doi.org/10.1093/rheumatology/keu035

Matsunami M, Ubara Y, Sumida K, Oshima Y, Oguro M, Kinoshita K, Tanaka K, Nakamura Y, Kinowaki K, Ohashi K, Fujii T. The efficacy and safety of anti-interleukin-6 receptor monoclonal blockade in a renal transplant patient with Castleman disease: early post-transplant outcome. BMC nephrology. 2018 Dec;19(1):1-5. https://doi.org/10.1186/s12882-018-1065-4

Matcham F, Scott IC, Rayner L, Hotopf M, Kingsley GH, Norton S, et al. The impact of rheumatoid arthritis on quality-of-life assessed using the SF-36: a systematic review and meta-analysis. InSeminars in arthritis and rheumatism 2014 Oct 1 (Vol. 44, No. 2, pp. 123-130). WB Saunders. https://doi.org/10.1016/j.semarthrit.2014.05.001

Calabresi E, Petrelli F, Bonifacio AF, Puxeddu I, Alunno A. One year in review 2018: pathogenesis of rheumatoid arthritis. Clin Exp Rheumatol. 2018 May;36(2):175-84..

McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. New England Journal of Medicine. 2011 Dec 8;365(23):2205-19.

https://doi.org/10.1056/NEJMra1004965

Choy EH, De Benedetti F, Takeuchi T, Hashizume M, John MR, Kishimoto T. Translating IL-6 biology into effective treatments. Nature Reviews Rheumatology. 2020 Jun;16(6):335-45. https://doi.org/10.1038/s41584-020-0419-z

Best JH, Vlad SC, Tominna L, Abbass I. Real-world persistence with tocilizumab compared to other subcutaneous biologic disease-modifying antirheumatic drugs among patients with rheumatoid arthritis switching from another biologic. Rheumatology and Therapy. 2020 Jun;7:345-55. https://doi.org/10.1007/s40744-020-00201-y

Nishimoto N, Terao K, Mima T, Nakahara H, Takagi N, Kakehi T. Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood, The Journal of the American Society of Hematology. 2008 Nov 15;112(10):3959-64.

https://doi.org/10.1182/blood-2008-05-155846

Abdullah RM, Khalil AA, Jassim NA, Gorial FI. Serum IL17 and IL-6 levels in a Sample of Iraqi Patients with Rheumatoid Arthritis: A Case Control Study. Chemistry and Materials Research. 2013;3(8).

Ibrahim RA, Al-Tae F. Interleukin-6 Serum Level and Single Nucleotide Gene-174 G/C promoter Polymorphism in Patients with Rheumatoid Arthritis/Iraq. Annals of the College of Medicine, Mosul. 2021 Dec 28;43(2):164-75.

https://doi.org/10.33899/mmed.2021.131144.1108

Al-Ani MM. Comparison between anti-filaggrin, anti-RA33 and anti-cyclic citrullinated peptide antibodies in the diagnosis of rheumatoid arthritis in iraqi patients. Iraqi J Comm Med. 2013;3:258-61..

Al-Karkhi MA, AL-Derzi AR, Zeiny SM, Jassim NA, Mahdi BM, Al-Ani MM. Correlation between Anti-infliximab and Anti-CCP Antibodies Development in Patients with Rheumatoid Arthritis Treated with Infliximab in Baghdad Teaching Hospital. IOSR Journal of Dental and Medical Sciences. 2015;14(11):95-100.